PTC Therapeutics signs licensing agreement with Roche
SMA is a genetic neuromuscular disorder that causes muscle weakness and is the leading genetic cause of death in infants and toddlers. One in every 10’000 children born is affected with the disorder, which currently has no effective treatment.
HBM BioVentures has invested USD 29 million in PTC over several rounds of financing and is its second largest shareholder. The company has two product candidates at the clinical stage of development and several preclinical and discovery stage programmes. PTC's most advanced product candidate isAtaluren(PTC124®), which is being evaluated in multiple Phase 2 and 3 clinical trials.
In accordance with HBM BioVentures’ valuation principles, the book value of our investment in PTC will not be changed in spite of this positive news.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.